Drugs

, Volume 52, Supplement 1, pp 8–14 | Cite as

A Preclinical Overview of Ebastine

Studies on the Pharmacological Properties of a Novel Histamine H1 Receptor Antagonist
  • David J. Roberts
Article

Summary

Ebastine is a novel histamine H1 receptor antagonist that combines potency with a rapid onset (fast absorption) and long duration (slow elimination) of action, at least partially mediated via the formation of an acid metabolite (carebastine) that is even more potent as an antihistamine. It shows clear selectivity for histamine H1 as opposed to H2 receptors, has moderate activity against other potential mediators of allergic phenomena such as leukotriene C4 and platelet-activating factor, and is clearly effective against anaphylactic reactions resulting from exposure of suitably sensitised tissues or animals to antigen.

By contrast, ebastine has negligible activity against acetylcholine (no atropine-like adverse effects on secretions and visual accommodation) and only poorly penetrates the blood-brain barrier (no sedative adverse effects).

Ebastine is without effects on the central nervous and cardiovascular systems, even after oral administration of high doses, and does not interact pharmacologically with a wide range of other drugs covering most areas of potential coadministration. Furthermore, ebastine showed no clinically relevant effects in a complete set of regulatory-required toxicity tests (including acute, chronic, reproductive, mutagenic and carcinogenic protocols) at doses giving blood concentrations representing high multiples of clinical exposure.

In conclusion, ebastine has a preclinical profile indicative of an excellent therapeutic ratio of desired effects to undesired effects.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Referenc

  1. 1.
    Roberts DJ. Fifty years of antihistamine research — from phenbenzamine (RP 2339) to ebastine (RP 64305). Drugs Today 1992; 28 Suppl. B: 1–9.Google Scholar
  2. 2.
    Dale HH. Croonian lectures on ‘some chemical factors in the control of the circulation’. Lancet 1929; 1: 1179–83, 1233–37, 1285–90.Google Scholar
  3. 3.
    Llupia J, Bou J, Fernandez AG, et al. Antihistamine, anti-allergic and related pharmacological properties of ebastine, a new selective antihistamine H1-receptor antagonist. Drugs Today 1992; 28 Suppl. B: 11–21.Google Scholar
  4. 4.
    Berga P, Puig J, Fernandez AG, et al. Preclinical safety studies with ebastine. I. Pharmacological effects on the central nervous system. Drugs Today 1992; 28 Suppl. B: 23–7.Google Scholar
  5. 5.
    Llenas J, Bou J, Massingham R. Preclinical safety studies with ebastine. II. Pharmacological effects on the cardiovascular system. Drugs Today 1992; 28 Suppl. B: 29–34.Google Scholar
  6. 6.
    Data on file, Laboratorios Almirall.Google Scholar
  7. 7.
    Berga P, Llenas J, Llupia J, et al. Preclinical safety studies with ebastine. III. Drug interactions. Drugs Today 1992; 28 Suppl. B: 35–44.Google Scholar
  8. 8.
    Martinez-Tobed A, Tarrus E, Segura J, et al. Pharmacokinetic studies in rats, dogs and man. Drugs Today 1992; 28 Suppl. B: 57–67.Google Scholar
  9. 9.
    Jauregui J, Roberts DJ. Preclinical safety studies with ebastine. IV. Acute, chronic and reproductive toxicity, mutagenicity and carcinogenicity. Drugs Today 1992; 28 Suppl. B: 45–56.Google Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • David J. Roberts
    • 1
  1. 1.Laboratorios Almirall, S.A.BarcelonaSpain

Personalised recommendations